Saranas

Saranas is a Houston-based medical device company focused on enhancing patient outcomes through innovative healthcare technology. Founded in 2013, the company has developed the Early Bird® Bleed Monitoring System, the first FDA-approved device for real-time monitoring of bleeding during and after endovascular and heart valve replacement procedures. This system utilizes bioimpedance sensors to detect internal bleeding early, allowing for timely intervention by physicians. Since its launch in 2019, the Early Bird system has been used to treat over 1,200 patients, helping to improve safety and reduce healthcare costs. Saranas is committed to expanding its clinical evidence through ongoing trials and is working on next-generation products, such as "Bird on a Wire," to support a wider range of endovascular procedures. The company is backed by significant venture capital investment, reflecting confidence in its technology and growth potential. Saranas primarily serves hospitals and healthcare providers, aiming to enhance procedural safety and patient care.

• Employees 12
• Founded 2013
• Annual Revenue $4555000
• Total Funding $29481489